New Brunswick, NJ, United States of America

Ravindra W Tejwani

This inventor holds 11 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents. Top assignees: Bristol-Myers Squibb Compnay, Acadia Pharmaceuticals Inc., Astrazeneca Ab. Active years: 2003-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ravindra W Tejwani. Retrieved from https://idiyas.com/inventor/ravindra-w-tejwani

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 90.9

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 6.1

ph-index = 5

Forward Citations = 83(Granted Patents)

Location History:

Somerset, NJ (US) (2003 - 2010)
New Brunswick, NJ (US) (2010 - 2014)
Monmouth Junction, NJ (US) (2015 - 2022)

Company Filing History:

9 out of 3,742

Bristol-Myers Squibb Compnay

patents

1 out of 94

Acadia Pharmaceuticals Inc.

Years Active: 2003-2022

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11452721 - Formulations of pimavanserin (2022-09-27),

2. 9198925 - Pharmaceutical formulations containing an SGLT2 inhibitor (2015-12-01),

3. 8716251 - Pharmaceutical formulations containing an SGLT2 inhibitor (2014-05-06),

4. 8361972 - Pharmaceutical formulations containing an SGLT2 inhibitor (2013-01-29),

5. 8221786 - Pharmaceutical formulations containing an SGLT2 inhibitor (2012-07-17),

6. 7851502 - Pharmaceutical formulations containing an SGLT2 inhibitor (2010-12-14),

7. 7659262 - Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di-amino acid salts, and mono- and di-amino acid ester salts (2010-02-09),

8. 7659261 - Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts (2010-02-09),

9. 7524832 - Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts and mono-and di-amino acid ester salts (2009-04-28),

10. 6855702 - Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts (2005-02-15),

11. 6670344 - Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts (2003-12-30),

Title: Ravindra W Tejwani: Innovator in Pharmaceutical Formulations

Introduction

Ravindra W Tejwani is a notable inventor based in New Brunswick, NJ (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 11 patents. His work primarily focuses on innovative formulations that enhance the efficacy of various medications.

Latest Patents

Among his latest patents, Ravindra has developed formulations of pimavanserin. These patents include capsules containing pimavanserin, processes for manufacturing said capsules, and pharmaceutical compositions that incorporate this compound. Additionally, he has created pharmaceutical formulations containing an SGLT2 inhibitor. These formulations are designed for oral use and include the medicament dapagliflozin or its propylene glycol hydrate, along with a pharmaceutical acceptable carrier, aimed at immediate release.

Career Highlights

Ravindra has had a distinguished career, working with prominent companies in the pharmaceutical industry. He has been associated with Bristol-Myers Squibb Company and AstraZeneca AB, where he contributed to the development of innovative drug formulations.

Collaborations

Throughout his career, Ravindra has collaborated with several talented individuals, including Mandar V Dali and Dilbir S Bindra. These collaborations have further enriched his work and contributed to the advancement of pharmaceutical sciences.

Conclusion

Ravindra W Tejwani's contributions to pharmaceutical formulations demonstrate his commitment to innovation in the field. His patents reflect a deep understanding of drug development and a dedication to improving patient outcomes.

Profile summary based on public USPTO records.